Evgen upbeat on start of glioblastoma research project
26th Oct 2023 11:08
(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.
Read moreEvgen Pharma doses first volunteers in SFX-01 trial
16th Nov 2022 14:05
(Sharecast News) - Clinical-stage drug developer Evgen Pharma has dosed the first group of healthy volunteers in its placebo-controlled, dose-escalating, randomised phase 1 and 1b clinical trial, it announced on Wednesday.
Read moreEvgen starts recruiting volunteers for trial of lead asset
12th Oct 2022 12:23
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the start of recruitment for the pharmacokinetic and pharmacodynamic trial in healthy volunteers, and the decision to commence an investigator-sponsored clinical study for the glioblastoma programme on Wednesday.
Read moreEvgen agrees fresh licensing deal with Spanish institutions
18th Jan 2022 11:48
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced a memorandum of understanding with the University of Seville, Consejo Superior de Investigaciones Científicas (CSIC) and Fundación Pública Andaluza Progreso y Salud on behalf of the Institute of Biomedicine of Seville on Tuesday, for second-generation sulforaphane analogues.
Read moreEvgen pleased with preclinical data on SFX-01
13th Jul 2021 15:36
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced preclinical data demonstrating that 'SFX-01' was effective in in-vitro models of certain blood cancers on Tuesday.
Read moreEvgen 'surprised and disappointed' by findings in SFX-01 trial
9th Jul 2021 10:33
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the results of the interim safety and futility assessment readout of the first 100 patients treated in the 'STAR' Covid-19 trial of its lead asset, 'SFX-01', on Friday.
Read moreEvgen upbeat on new data on potential breast cancer treatment
14th Jun 2021 11:00
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced new preclinical data on Monday, which showed 'SFX-01' could be of benefit to metastatic breast cancer (mBC) patients who had become resistant to CDK4/6 inhibitors.
Read moreEvgen appoints Helen Kuhlman as chief business officer
22nd Mar 2021 09:08
(Sharecast News) - Clinical-stage drug development company Evgen announced on Monday that Helen Kuhlman had been appointed to the post of chief business officer, taking up the role from 1 April.
Read moreEvgen Covid-19 trial given all-clear on safety and data
11th Mar 2021 15:12
(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Thursday that after a review of the first 60 patients enrolled, the data safety monitoring committee for the 'STAR' Covid-19 trial had concluded that there were no concerns over patient safety or data quality that would prevent its continuation.
Read moreEvgen makes progress with recruitment in 'STAR' trial
17th Feb 2021 15:10
(Sharecast News) - Clinical stage drug development company Evgen Pharma said on Wednesday that a total of 102 patients had been recruited and randomised to the 'STAR', or 'SFX-01 Treatment for Acute Respiratory infections', trial.
Read moreEvgen Pharma performs in line with forecasts in first half
10th Dec 2020 15:45
(Sharecast News) - Clinical-stage drug development company Evgen Pharma reported financial performance in line with its expectations in its first half on Thursday, with revenue coming in at £0.19m, compared to nil a year earlier.
Read moreEvgen doses first patients in 'STAR' respiratory trial
23rd Nov 2020 12:22
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced on Monday that the first patient had now been enrolled and dosed in the 'STAR' trial of its 'SFX-01' treatment for acute respiratory infections.
Read moreEvgen gets full approval for SFX-01 trial in Covid-19 patients
23rd Oct 2020 11:49
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced on Friday that all necessary regulatory approvals had now been received for the 'STAR' trial of SFX-01 treatment for Acute Respiratory Infections.
Read moreEvgen Pharma licences technology to Juvenescence
15th Sep 2020 08:41
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the licensing of its sulforaphane stabilisation technology in a number of non-pharmaceutical applications to Juvenescence on Tuesday.
Read moreEvgen's 'SFX-01' to be tested with Covid-19 patients
17th Jun 2020 12:01
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced its participation in the recently-notified funding initiative for Covid-19 clinical trials by the medical research charity LifeArc on Wednesday.
Read more